Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer

Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer

Fibroblast Growth Factor Receptors (FGFRs) are a family of receptor tyrosine kinases expressed on a plethora of cell membranes. They play crucial roles in both embryonic development and adult tissue functions. There is an increasing amount of evidence that FGFR-mediated oncogenesis is mainly related...

Full description

Bibliographic Details
Main Authors: Delfina Popiel, Aleksandra Stańczak, Monika Skupińska, Agata Mikołajczyk, Paulina Stańczak, Filip Mituła, Joanna Hucz-Kalitowska, Kinga Jastrzębska, Damian Smuga, Jakub Dominowski, Monika Delis, Krzysztof Mulewski, Wojciech Pietruś, Daria Zdżalik-Bielecka, Karolina Dzwonek, Monika Lamparska-Przybysz, Abdellah Yamani, Patrycja Olejkowska, Natalia Piórkowska, Krzysztof Dubiel, Maciej Wieczorek, Jerzy Pieczykolan
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Oncology
Subjects:
FGFR
FGFR inhibitor
FGFR aberrations
solid tumor
targeted therapy
CPL304110
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1293728/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1293728/full

Similar Items